Evaluation of the noradrenergic system in Parkinson’s disease: an 11C-MeNER PET and neuromelanin MRI study by Sommerauer M et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Sommerauer M, Fedorova TD, Hansen AK, Knudsen K, Otto M, Jeppesen J, 
Frederiksen Y, Blicher JU, Geday J, Nahimi A, Damholdt MF, Brooks DJ, 
Borghammer P. 
Evaluation of the noradrenergic system in Parkinson’s disease: an 11C-
MeNER PET and neuromelanin MRI study.  
Brain 2017, awx348. 
 
 
Copyright: 
This is the authors’ accepted manuscript of an article that has been published in its final definitive 
form by Oxford University Press, 2017. 
DOI link to article: 
https://doi.org/10.1093/brain/awx348  
Date deposited:   
31/10/2017 
Embargo release date:  
18 December 2018  
1 
	
Evaluation of the noradrenergic system in Parkinson’s disease  
An 11C-MeNER positron emission tomography & neuromelanin magnetic 
resonance imaging study 
 
Michael Sommerauer1,2, Tatyana D Fedorova1, Allan K Hansen1, Karoline Knudsen1, Marit 
Otto3, Jesper Jeppesen3, Yoon Frederiksen4, Jakob U Blicher5, Jacob Geday6, Adjmal Nahimi1, 
Malene F Damholdt4, David J Brooks1,7,8, and Per Borghammer1* 
  
1Aarhus University Hospital, Department of Nuclear Medicine and PET Centre, Aarhus, 
Denmark 
2Department of Neurology, University Hospital Cologne, Cologne, Germany 
3Aarhus University Hospital, Department of Clinical Neurophysiology, Aarhus, Denmark 
4Aarhus University, Department of Clinical Medicine & Department of Psychology, Aarhus, 
Denmark 
5Center of Functionally Integrative Neuroscience, Aarhus University, Denmark 
6Aarhus University Hospital, Department of Neurology, Aarhus, Denmark 
7Division of Neuroscience, Department of Medicine, Imperial College London, London, UK 
8Division of Neuroscience, Newcastle University, Newcastle, UK 
 
 
*Corresponding author: Per Borghammer, MD, PhD, DMSc 
Email: perborgh@rm.dk 
Phone: +45 2826 1039 
Fax: +45 7846 3020 
Department of Nuclear Medicine and PET Centre 
Aarhus University Hospital 
Nørrebrogade 44, Building 10G 
8000 Aarhus C, Denmark 
 
Running title: Noradrenergic function in PD 
Word count: Abstract: 
Manuscript: 
Figures / tables: 
References: 
288 
3937 
6 
37  
2 
	
Abstract 
Pathological involvement of the noradrenergic locus coeruleus occurs early in Parkinson’s disease, 
and widespread noradrenaline reductions are found at post-mortem. Rapid eye movement sleep 
behavior disorder (RBD) accompanies Parkinson’s disease and its presence predicts an unfavorable 
disease course with a higher propensity to cognitive impairment and orthostatic hypotension. MRI 
can detect neuromelanin in the locus coeruleus while 11C-MeNER PET is a marker of noradrenaline 
transporter availability. Here, we use both imaging modalities to study the association of RBD, 
cognition and autonomic dysfunction in Parkinson’s disease with loss of noradrenergic function. 
Thirty non-demented Parkinson’s disease patients (16 patients with RBD and 14 without RBD, 
comparable across age (66.6 ± 6.7 years), sex (22 males), and disease stage (Hoehn & Yahr, 2.3 ± 
0.5)), had imaging of the locus coeruleus with neuromelanin sensitive MRI and brain noradrenaline 
transporter availability with 11C-MeNER PET. RBD was confirmed with polysomnography; 
cognitive function was assessed with a neuropsychological test-battery, and blood pressure changes 
on tilting were documented; results were compared to 12 matched control subjects. We found that 
Parkinson’s disease patients with RBD showed decreased locus coeruleus neuromelanin signal on 
MRI (p < 0.001) and widespread reduced binding of 11C-MeNER (p < 0.001) which correlated with 
amount of REM sleep without atonia. Parkinson’s disease with RBD was also associated with a 
higher incidence of cognitive impairment, slowed electroencephalographic activity, and orthostatic 
hypotension. Reduced 11C-MeNER binding correlated with electroencephalographic slowing, 
cognitive performance, and orthostatic hypotension. In conclusion, reduced noradrenergic function 
in Parkinson’s disease was linked to the presence of RBD and associated with cognitive 
deterioration and orthostatic hypotension. Noradrenergic impairment may contribute to the high 
prevalence of these non-motor symptoms in Parkinson’s disease, and may be of relevance when 
treating these conditions in Parkinson’s disease.  
 
Keywords: Parkinson’s disease, REM sleep behavior disorder, positron emission tomography, 
noradrenaline 
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Introduction 
Noradrenergic innervation of the brain arises almost exclusively from the neuromelanin containing 
cells of the locus coeruleus. Depositions of aggregated alpha-synuclein in the locus coeruleus occur 
early in Braak stage 2 of Parkinson’s disease (Braak et al., 2001). Post-mortem studies have 
detected a substantial noradrenergic deficit in Parkinson’s disease patients (Kish et al., 1984). 
However, in vivo assessment of the noradrenergic system has been hampered by the lack of suitable 
imaging tools. Recently, neuromelanin-sensitive magnetic resonance imaging (MRI) sequences 
have been introduced, capable of delineating the pigment in the cell bodies in the locus coeruleus 
(Keren et al., 2015). Additionally, 11C-MeNER, a positron emission tomography (PET) reboxetine 
analogue with a high specificity for noradrenaline transporters has been developed (Schou et al., 
2003). These imaging modalities have been successfully used to study locus coeruleus changes and 
noradrenergic transporter function in Parkinson’s disease (Garcia-Lorenzo et al., 2013; Nahimi et 
al., 2017). 
Rapid eye movement (REM) sleep behavior disorder (RBD) is a sleep disorder defined by deficient 
muscle atonia and dream enactment during REM sleep. Parkinson’s disease patients with RBD 
(PDRBD+) are at high risk of developing cognitive impairment (Jozwiak et al., 2017). Additionally, 
this subpopulation also displays a high prevalence of autonomic disturbances (Postuma et al., 
2008). Interestingly, these non-motor symptoms often coincide suggesting a common 
neurobiological factor (Udow et al., 2016). The noradrenergic system mediates cognitive attention, 
regulates the sleep cycle and influences cardiac function via widespread projections from the locus 
coeruleus to the cortex, brainstem nuclei and the hypothalamus (Rodovalho et al., 2006; Vazey and 
Aston-Jones, 2012); thus, noradrenergic degeneration might be the candidate. The pathophysiology 
of RBD is not fully understood, but rodent models indicate a substantial role of the sublaterodorsal 
nucleus in establishing REM atonia, which corresponds to the locus subcoeruleus in humans 
(Valencia Garcia et al., 2017). These cells contain neuromelanin in humans and are located 
dorsoventrally to the locus coeruleus; both parts are often assimilated into the 
subcoeruleus/coeruleus complex (Braak et al., 2001; Garcia-Lorenzo et al., 2013). Recent 
neuromelanin sensitive MR sequences have revealed a loss of neuromelanin signal from this 
complex in PDRBD+ (Garcia-Lorenzo et al., 2013). We hypothesize that damage to the 
subcoeruleus/coeruleus complex might represent a common pathway for RBD genesis, cognitive 
decline, and orthostatic dysregulation.  
4 
	
The objective of this combined 11C-MeNER PET and neuromelanin-sensitive MRI study was to 
examine the hypothesis that the noradrenergic system is more severely affected in PDRBD+ 
compared to Parkinson’s disease patients without RBD (PDRBD-). Additionally, we aimed to 
investigate the relationship between levels of noradrenergic function, cognition and autonomic 
regulation in Parkinson’s disease.  
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Material and methods 
Study design and participants 
We recruited 30 Parkinson’s disease patients distributed as 14 PDRBD- and 16 PDRBD+ patients, 
comparable in age, sex, disease stage, and performance on the Montreal Cognitive Assessment 
(MoCA) (Table 1). Inclusion criteria were: Diagnosis of Parkinson’s disease according to the 
Movement Disorder Society (MDS) consensus criteria (Postuma et al., 2015), age 50 - 85 years, a 
geriatric depression scale (GDS-15) score <6 and MoCA >22. Exclusion criteria were: A diagnosis 
of dementia, medication interacting with the noradrenaline transporter, and significant white matter 
lesions. Patients were recruited through advertisement in the Danish Parkinson’s disease magazine 
and from collaborating neurological clinics. Total levodopa-equivalent daily doses were calculated 
as previously recommended (Tomlinson et al., 2010). Motor symptoms were quantified using the 
MDS Unified Parkinson’s disease Rating Scale part III (MDS-UPDRS III) after 12 hours of 
medication abstinence. Olfaction was tested with the 16-item Sniffin’ Sticks, RBD symptoms were 
assessed using the RBD symptom questionnaire (RBDSQ). Parkinson’s disease patients were 
compared to 12 age and sex matched, cognitive normal (MoCA >26) and non-depressed (GDS-15 
<6) healthy control subjects without history of neurological disorders and with normal brain MRI 
(Table 1). Six additional healthy control subjects - part of an in-house neuromelanin MRI control 
sample - fulfilling aforementioned criteria were included for neuromelanin MRI analysis. All 
healthy control subjects were recruited through newspaper advertisements. 
The study was approved by the local ethical committee; all subjects gave informed written consent 
according to the Declaration of Helsinki. 
 
MRI 
Subjects were scanned with a 3 Tesla SIEMENS MAGNETOM TRIO scanner; the protocol 
included T1 and fluid-attenuated inversion recovery images. Neuromelanin sensitive images were 
acquired with 2D axial turbo spin echo T1-weighted sequences (repetition time / echo time: 600 
ms / 9.9 ms, 16 averages, voxel size: 0.4 × 0.4 × 1.8 mm). Planes were acquired perpendicular to 
the dorsal brainstem, and a locus coeruleus-to-pons ratio was calculated using PMOD 3.8: A 
template volume of interest (VOI) for each side of the locus coeruleus, derived from previously 
published Montreal Neurological Institute atlas coordinates (Keren et al., 2009), was transformed 
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to the individual MRI, and adjusted manually for precise localization if needed. The 10 voxels with 
highest intensity were extracted from each VOI and divided by the background level derived from 
a rectangular VOI centered in the pons, and both values were averaged. Blinded inter-rater 
assessment (MS and TF) revealed high agreement (R² = 0.913), and the average of both raters of 
MRI neuromelanin locus coeruleus-to-pons ratios was taken for group comparisons. To assess the 
association of MRI and 11C-MeNER PET signals, we interrogated correlations between locus 
coeruleus-to-pons ratios and 11C-MeNER DVRs. 
 
11C-MeNER PET 
11C-MeNER radiosynthesis was performed as described previously (Nahimi et al., 2017). After a 
transmission scan and at the start of a bolus administration of 11C-MeNER, a 90-minute dynamic 
PET scan was acquired with an ECAT HRRT in list mode. We analyzed PET images with relevant 
toolboxes of PMOD 3.8, including time frame realignment for motion correction. All PET images 
were then normalized into Montreal Neurological Institute space including rigid matching of 
subject’s PET to the anatomical MRI, and MRI segmentation. We defined six noradrenaline 
transporter rich regions (thalamus, hypothalamus, red nucleus, locus coeruleus, median raphe, 
dorsal raphe) for VOI analysis and used the occipital cortex (OC) as a reference region; thalamus 
and OC were defined from the built-in Hammers N30R83 atlas. VOIs of the locus coeruleus and 
dorsal and median raphe were drawn accordingly to published details (Keren et al., 2009; Kranz et 
al., 2012). Red nucleus VOIs were defined on individual FLAIR images and transformed to 
Montreal Neurological Institute space; hypothalamus VOIs were defined by their surrounding 
structures. To optimize kinetic modelling, we smoothed PET images with a 4 mm Gaussian filter 
and extracted time activity curves from VOIs for calculation of distribution volume ratios (DVRs) 
with the simplified reference tissue model 2 (SRTM2) for group comparisons. For illustration 
purpose (Figure 1), parametric maps of SRTM2 DVRs were generated. More details of PET 
analysis are given in the supplementary material. 
 
Polysomnography and electroencephalogram 
We used a SOMNOscreenTM plus Tele+Video device for overnight video-polysomnography 
including ten electroencephalogram electrodes, right and left electrooculogram, nasal pressure 
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monitoring, thoracic and abdominal effort belts, electrocardiogram, pulse oximetry, 
electromyogram of the submental and tibialis anterior muscles, and video monitoring. Presence of 
RBD was judged according to the current consensus criteria from the American Academy of Sleep 
Medicine. Quantitative electromyogram analysis of ‘phasic’ (representing brief activity less than 
15 s), ‘tonic’ (representing sustained activity longer than 15 s), and ‘any’ (representing any activity) 
submental muscle activity during REM sleep was performed with a validated computer algorithm, 
which was recently developed by our group and shown to have high congruency with human visual 
ratings (R² > 0.9). The semi-automated computer algorithm was based on previously proposed 
visual scoring criteria by McCarter and colleagues (McCarter et al., 2014). As REM sleep atonia 
is supposed to be mediated by brainstem nuclei interplay (Boeve et al., 2007), we correlated the 
11C-MeNER PET signal in the corresponding areas (locus coeruleus and raphe nuclei) with 
measures of quantitative electromyogram analysis.  
Electroencephalography was performed under ambient conditions with the subject awake and 
resting with closed eyes. We extracted 30 s artifact-free epochs to calculate alpha (8 - 13 Hz) and 
theta (4 - 8 Hz) power, and background frequency (correspondent to the frequency with highest 
power in the spectrum) using the Natus Viewer software and the built-in band power report. Signals 
of the O1 and O2 electrodes were pre-filtered with 3 Hz high-pass and 15 Hz low-pass filters, and 
results of both electroencephalography electrodes were averaged and used for group comparisons. 
Slowing of electroencephalographic background frequency was reported to herald cognitive 
decline in Parkinson’s disease patients (Klassen et al., 2011; Latreille et al., 2016), and as locus 
coeruleus firing pattern was reported to have high congruency to the cortical 
electroencephalography signal (Bari and Aston-Jones, 2013), we selected the 11C-MeNER binding 
in the locus coeruleus for correlation analysis with electroencephalography.  
 
Neuropsychological assessment 
Cognition was assessed adhering to the 2012 MDS diagnostic criteria for mild cognitive 
impairment in Parkinson’s disease (Litvan et al., 2011). Mild cognitive impairment was diagnosed 
when two cognitive tests revealed z-scores below -1.5 and there was a history of cognitive 
complaints reported by the subject or spouse on our questionnaire (Koster et al., 2015). Tests 
included Rey auditory verbal learning test, and the location learning test for memory domain; digit 
span backwards, letter number sequencing task, and Stroop color and word test for working 
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memory; Wisconsin card sorting test, and phonemic verbal fluency (-s version) for executive 
functioning; similarities test, semantic verbal fluency (animals), and the 30 item Boston naming 
test for language abilities; Benton judgement of line orientation, clock drawing and visual puzzles 
for visuospatial function. Z-scores for each cognitive domain were calculated based on published 
age corrected norms, if available, and from an in-house Danish cohort of healthy subjects matched 
for age. A composite score of the average of the five domain z-scores was calculated to estimate 
global cognitive performance. This global score was used for correlation analysis with the 11C-
MeNER PET signal of the locus coeruleus. Premorbid cognitive function was estimated with the 
WAIS-IV vocabulary test and scale scores were comparable across groups (healthy control, 10.6 ± 
2.4, PDRBD-, 10.4 ± 2.0, PDRBD+, 9.7 ± 1.7; p = 0.669).  
 
Autonomic assessment 
Symptoms of autonomic disturbances were assessed with rating scales for outcomes in Parkinson’s 
disease - autonomic (SCOPA-AUT); due to incomplete response rates on items 22 - 25 (questions 
about sexual ability), these sections were excluded. After >15 min rest in the supine position, blood 
pressure was measured for three consecutive minutes after tilting. Orthostatic hypotension was 
defined as systolic pressure drop of 20 mmHg or diastolic pressure drop of 10 mmHg within the 
first three minutes of standing (The Consensus Committee of the American Autonomic Society 
and the American Academy of Neurology, 1996). Blood pressure measurements were not 
undertaken at a fixed time of day, but were usually performed between 10 am and 2 pm. We 
calculated the mean changes of systolic pressure and diastolic pressure during the three minutes of 
upright position and subtracted the mean from the supine blood pressure for group comparisons. 
We selected the 11C-MeNER PET signals of locus coeruleus and hypothalamus, which are 
noradrenergic centers of blood pressure regulation (Rodovalho et al., 2006), for correlation with 
blood pressure changes. Blood pressure measurements were not undertaken in 2 PDRBD+ subjects 
because of atrial fibrillation and beta-blocker therapy, and in 2 PDRBD+ and 1 healthy control 
subjects because of technical failure of the blood pressure monitor. 
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Statistical analysis 
We interrogated the data with the Statistical Package for the Social Sciences (SPSS) version 24. 
Group data is presented as mean ± standard deviation if not otherwise stated. Group comparisons 
were performed with one-way analyses of variances (ANOVA), Student’s t-tests, Mann-Whitney 
tests, Kruskal-Wallis tests, and chi-square tests as appropriate; a normal distribution of data was 
assessed with Shapiro-Wilk tests, Q-Q plots, and box plots. Univariate correlation analyses were 
calculated with Pearson’s r and Spearman’s rho as appropriate. For VOI-based PET analysis, a 
linear mixed model for repeated measures with the random effect ‘subject’, the between-subjects 
factor ‘group’, and the within-subjects factor ‘brain region’ was calculated; the interaction term of 
‘brain region’ * ‘group’ was included in model calculation. Significance was accepted at p < 0.05. 
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Results 
Decreased noradrenergic imaging-markers in PDRBD+ patients 
In accordance with their RBD diagnosis, PDRBD+ patients scored higher on the RBDSQ and had 
extensive epochs of REM sleep without atonia for all three muscle activity categories. The 
Parkinson’s disease subgroups and healthy control subjects were otherwise comparable with regard 
to demographic and clinical characteristics (Table 1). 11C-MeNER DVRs differed significantly 
between the groups and the PDRBD+ patients exhibited the lowest mean values in all examined brain 
regions (group effect p < 0.001; healthy control vs PDRBD-, p = 0.027 , healthy control vs PDRBD+, 
p <  0.001, and PDRBD- vs PDRBD+, p =  0.001). The interaction term of ‘brain region’ * ‘group’ was 
highly significant (p = 0.004), and the decrease of regional 11C-MeNER DVRs was most 
pronounced in brainstem nuclei in PDRBD+ patients;  see Figure 1. PDRBD+ patients also displayed 
the lowest neuromelanin locus coeruleus-to-pons ratio on MRI (group effect p < 0.001, healthy 
control vs PDRBD-, p = 0.014, healthy control vs PDRBD+, p < 0.001, and PDRBD- vs PDRBD+, p = 
0.026; Figure 2 A+B). Locus coeruleus-to-pons ratios from neuromelanin MRI correlated with 
thalamic 11C-MeNER DVR levels in pooled analysis but did not correlate with other regional 11C-
MeNER DVR levels (rho = 0.339, p = 0.030 for thalamus; Figure 2 C).  
The amount of muscle activity in REM sleep correlated negatively with 11C-MeNER DVR of the 
locus coeruleus in PDRBD+ patients (r = -0.623, p = 0.013 for ‘any’, r = -0.678, p = 0.006 for ‘tonic’, 
and r = -0.551, p = 0.033 for ‘phasic’ activity; Figure 3); no correlations were significant between 
amount of electromyogram activity and raphe 11C-MeNER DVR or MRI locus coeruleus-to-pons 
ratio. 
 
Correlation of noradrenergic imaging-markers with cognition and autonomic 
regulation 
PDRBD+ patients showed a lower performance in all cognitive domains which reached significance 
in the visuospatial domain, and they had an increased prevalence of mild cognitive impairment 
(Table 2). PDRBD+ patients also showed significantly slower electroencephalographic background 
frequency compared to PDRBD- patients and healthy control, and by extension, higher theta power 
and a lower alpha/theta power ratio (Table 2). 11C-MeNER DVRs of the locus coeruleus correlated 
with global cognitive performance in Parkinson’s disease patients as well as in pooled analysis 
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with healthy control subjects (r = 0.399, p = 0.029, and r = 0.394, p = 0.010, respectively); similar 
correlations were obtained with electroencephalographic background frequency (r = 0.404, p = 
0.033, and r = 0.490, p = 0.001 for pooled analysis, respectively), see Figure 4 A-B. MRI locus 
coeruleus-to-pons ratios did not correlate with background frequency or cognitive performance.  
Subjective complaints of autonomic symptoms were more prevalent in Parkinson’s disease patients 
compared to healthy control subjects and orthostatic hypotension was most prevalent in PDRBD+ 
patients (50%, p = 0.026). Upon tilting, PDRBD+ patients exhibited a blunted blood pressure 
response with a significant fall of systolic pressure (-12.2 ± 17.9 mmHg, p = 0.019) (Table 2). 
Blood pressure falls correlated significantly with 11C-MeNER DVRs of the locus coeruleus and 
hypothalamus in the pooled analysis (systolic pressure: r = 0.375, p = 0.022 & r = 0.286, p = 0.086; 
diastolic pressure: r = 0.339, p = 0.040 & r = 0.367, p = 0.025), but significance was not achieved 
in the analysis of Parkinson’s disease patients alone (Figure 4 C-D). No correlation was observed 
between MRI locus coeruleus-to-pons ratios and blood pressure changes. 
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Discussion 
In this study, we examined structure and function of the noradrenergic system in Parkinson’s 
disease patients with multimodal imaging. We targeted the pigmented cell bodies of the locus 
coeruleus with neuromelanin sensitive MRI, and noradrenaline transporters in relevant brain 
regions with 11C-MeNER PET. Both modalities showed marked reductions of signal in Parkinson’s 
disease patients, most pronounced in PDRBD+ patients, and decline of 11C-MeNER binding was 
associated with magnitude of abnormal muscle activity during REM sleep. PDRBD+ patients showed 
slowed electroencephalography activity and a higher incidence of cognitive impairment and 
orthostatic hypotension. These conditions were associated with reduced 11C-MeNER binding in 
regulatory noradrenergic brain areas. 
Parkinson’s disease patients exhibited the lowest 11C-MeNER binding in all examined brain 
regions as well as the lowest neuromelanin signal on MRI; however, neuromelanin MRI and 11C-
MeNER PET signals were not well correlated. Several studies on Parkinson’s disease patients and 
animal lesion models have reported a lack of correlation between dopaminergic neuronal density 
in the substantia nigra and the integrity of striatal dopaminergic terminals. When data from subjects 
with and without dopaminergic deficit were pooled, however, a correlation was observed (Karimi 
et al., 2013; Kraemmer et al., 2014). A “dying-back” concept of the dopaminergic system has been 
postulated in the context of Parkinson’s disease, i.e. axonal and terminal degeneration prior to 
neuronal cell loss, which may also apply to the noradrenergic system (Cheng et al., 2010). 
Nevertheless, dying back does not explain an absent correlation between structural and functional 
imaging modalities in the locus coeruleus itself. Monoaminergic transporters and receptors undergo 
adaptive changes in Parkinson’s disease and so their availability may not show a proportional 
relationship with the magnitude of neuronal death of corresponding cell bodies. Additionally, while 
the noradrenergic locus coeruleus signalling is largely integrative, neurons display significant 
heterogeneity in their regional projections (Kebschull et al., 2016). Thus, it is perhaps not 
unexpected that the neuromelanin MRI signal as a marker of the integrity of locus coeruleus cell 
bodies did not correlate with regional noradrenalin transporter density measured with 11C-MeNER 
PET in brain structures exhibiting differential noradrenergic inputs. However, since PDRBD+ 
patients showed decreased signal on both imaging modalities, it suggests that noradrenergic 
damage is profound and widespread in this Parkinson’s disease subpopulation. 
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In addition to the difference of PDRBD+ patients as a group, we also detected a negative correlation 
of 11C-MeNER binding in the locus coeruleus with the amount of muscle activity in REM sleep, 
strengthening the association of noradrenergic alterations to key symptoms of RBD. Of note, 
noradrenergic enhancing drugs increase the amount of muscle activity during REM sleep, and the 
locus coeruleus is known to cease firing during REM sleep as part of a sleep-stage switch (Lu et 
al., 2006). This evidence points to a substantial role of noradrenergic signalling in normal REM 
sleep regulation and as a mediator of REM sleep atonia. However, converging evidence from 
animal research suggests that activation of the glutamatergic sublaterodorsal nucleus establishes 
REM atonia (Valencia Garcia et al., 2017). Nevertheless, it remains unsolved, whether the 
homologous locus subcoeruleus in humans is also glutamatergic, especially since it contains 
neuromelanin pigment, which is typically expressed in catecholaminergic neurons. Additionally, 
cells in the locus subcoeruleus express α2-adrenergic receptors, which when activated inhibit the 
output from these cells that is necessary to establish REM atonia (Yang et al., 2014). Thus, deficient 
noradrenergic signaling might interact at the level of the sleep stage switch, resulting in inefficient 
REM sleep stage transition with ‘leaking’ of muscle activity during REM sleep. Alternatively, non-
physiological activation of the nucleus subcoeruleus during REM sleep may result from insufficient 
inhibition from the locus coeruleus. Our findings may also simply represent a mutual affection of 
the locus subcoeruleus/coeruleus complex in Parkinson’s disease, as these structures are well 
interconnected and situated closely together (Braak et al., 2001). It would have been interesting to 
explore correlation of RBD symptom duration with noradrenergic imaging parameters in our PD 
cases but many cases were unable to accurately date the onset of their sleep disorder. 
A heterogeneous clinical presentation and prognosis of Parkinson’s disease patients is increasingly 
recognized, and in a recent longitudinal study, the presence of RBD, mild cognitive impairment, 
and orthostatic hypotension were the best predictors of a diffuse/malignant phenotype of 
Parkinson’s disease (Fereshtehnejad et al., 2015). In our study, PDRBD+ patients also showed higher 
propensity to cognitive impairment and orthostatic hypotension in agreement with previous studies 
(Postuma et al., 2008; Udow et al., 2016; Jozwiak et al., 2017). Hence, a common neurobiological 
premise for RBD, cognitive deterioration, and orthostatic disturbances in Parkinson’s disease 
seems plausible and indeed, we detected associations between the noradrenergic system as 
measured with 11C-MeNER PET and all three conditions. 11C-MeNER not only correlated with 
global cognitive performance but also with electroencephalographic activity, which was slowed in 
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PDRBD+ patients. Slowing of electroencephalography is commonly seen in several forms of 
dementia, and was previously shown to be highly predictive for the development of dementia in 
Parkinson’s disease (Klassen et al., 2011). However, maintaining healthy cognition is dependent 
on several neurotransmitter systems and particularly the loss of cholinergic signalling is a well-
known cause of cognitive decline in Parkinson’s disease (Bohnen et al., 2015). Nevertheless, locus 
coeruleus terminals exhibit a brain-wide distribution and are known to modulate various 
neurotransmitters via adaption of their firing pattern and divergent post-synaptic effects due to 
different noradrenergic receptors (Schwarz and Luo, 2015). This may be particularly important in 
early to mid-stage Parkinson’s disease when alpha-synuclein pathology has not yet spread to the 
majority of cortical regions, but is mostly confined to brainstem areas (Braak et al., 2001). 
Accordingly, and given the results of the present study, the noradrenergic system should be a 
considered therapeutic target in Parkinson’s disease. Some studies have already pointed to 
beneficial effects of noradrenergic enhancement by atomoxetine and droxidopa on cognition and 
blood pressure control (Weintraub et al., 2010; Kaufmann et al., 2014), and studies with these 
compounds are currently on-going.  
Several limitations of our study should be noted. First, the sample size of 42 subjects is modest, 
but still represents a high standard for PET studies. Some VOIs used in the study are not clearly 
defined on anatomical MRI and we had to use previously recommended definitions in Montreal 
Neurological Institute space coordinates (Keren et al., 2009; Kranz et al., 2012). Blood pressure 
regulating medication was not withdrawn prior to orthostatic testing; however, prevalence of 
treatment did not differ between groups. We also did not control for circadian variation of blood 
pressure regulation as measurements were not performed at a fixed daytime. These factors might 
have contributed to reduced statistical power of our blood pressure analysis. 
In conclusion, we found that noradrenergic impairment in Parkinson’s disease is linked to the 
presence of RBD and correlated with its key characteristic of increased muscle activity during 
REM sleep. Noradrenergic impairment might also contribute to the high prevalence of cognitive 
decline and orthostatic hypotension in Parkinson’s disease patients, especially in patients with 
RBD, and might point to new options for treatment of these conditions.  
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Supplementary material  
11C-MeNER PET image acquisition and choice of reference region 
A six minute transmission scan was acquired for attenuation correction prior to each 11C-MeNER 
emission scan. Radiotracer doses of intravenously injected 11C-MeNER did not differ significantly 
between groups (healthy control, 646.3 ± 119.6, PDRBD-, 707.4 ± 63.6, PDRBD+, 707.8 ± 138.5 MBq; 
p = 0.243). Dynamic PET was acquired over 90 minutes in list-mode and then rebinned into 27 
time frames (6 x 30 s, 3 x 60 s, 2 x 120 s, and 16 x 300 s). Image series were reconstructed using 
3D OSEM (ordered subsets expectation maximization) and resolution recovery modelling (PSF) 
with 10 iterations and 16 subsets. Reconstructed images consisted of 207 axial image slices with 
an isotropic 1.22 mm voxel size.  
Despite brain-wide noradrenergic innervation, regions with variable noradrenaline re-uptake 
transporter densities have been identified,1 with lowest binding of the MeNER ligand to the 
occipital cortex in humans.2 In line with these results, binding of 11C-MeNER in the occipital cortex 
was not significantly displaceable by pharmacologic interventions on the noradrenaline 
transporter,3,4 providing evidence that the occipital cortex is a suitable reference region to study 
specific binding in brain regions with higher expression of noradrenaline transporters (i.e. 
thalamus, hypothalamus, red nucleus, locus coeruleus, and raphe nuclei).1-7 To calculate specific 
binding with the simplified reference tissue model 2 (SRTM2), the efflux rate constant of the 
reference region (k2’) has to be defined and is typically fixed across subjects. The average k2’ for 
the occipital cortex was previously reported to be 0.021 min−1,6 and was used in our study, since it 
was in accordance with estimates derived from coupled fits of k2’ within the SRTM2 model using 
all studied high binding areas (thalamus, hypothalamus, red nucleus, locus coeruleus, and raphe 
nuclei): averaged k2’ = 0.022 min−1 for all studied 42 subjects without differences between 
Parkinson’s disease patients and healthy control subjects. 
 
1. Smith HR, Beveridge TJ, Porrino LJ. Distribution of norepinephrine transporters in the non-
human primate brain. Neuroscience 2006; 138(2): 703-14. 
2. Schou M, Halldin C, Pike VW, et al. Post-mortem human brain autoradiography of the 
norepinephrine transporter using (S,S)-[18F]FMeNER-D2. Eur Neuropsychopharmacol 2005; 
15(5): 517-20. 
17 
	
3. Hannestad J, Gallezot JD, Planeta-Wilson B, et al. Clinically Relevant Doses of 
Methylphenidate Significantly Occupy Norepinephrine Transporters in Humans In Vivo. Biol 
Psychiat 2010; 68(9): 854-60. 
4. Logan J, Ding YS, Lin KS, Pareto D, Fowler J, Biegon A. Modeling and analysis of PET studies 
with norepinephrine transporter ligands: the search for a reference region. Nucl Med Biol 2005; 
32(5): 531-42. 
5. Schou M, Halldin C, Sovago J, et al. Specific in vivo binding to the norepinephrine transporter 
demonstrated with the PET radioligand, (S,S)-[11C]MeNER. Nucl Med Biol 2003; 30(7): 707-
14. 
6. Pietrzak RH, Gallezot JD, Ding YS, et al. Association of posttraumatic stress disorder with 
reduced in vivo norepinephrine transporter availability in the locus coeruleus. JAMA Psychiatry 
2013; 70(11): 1199-205. 
7. Li CS, Potenza MN, Lee DE, et al. Decreased norepinephrine transporter availability in obesity: 
Positron Emission Tomography imaging with (S,S)-[(11)C]O-methylreboxetine. Neuroimage 
2014; 86: 306-10. 
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Figure Legends 
 
Figure 1: 11C-MeNER Distribution volume ratios (DVR) of PD patients and control subjects  
A. Averaged 11C-MeNER DVR in noradrenaline transporter rich regions (Thal = thalamus, Hypo 
= hypothalamus, RN = red nucleus, LC = locus coeruleus, DR = dorsal raphe, MR = median raphe) 
of 12 healthy controls, 14 PDRBD-, and 16 PDRBD+ subjects; error bars indicate standard error of the 
mean (SEM); pair-wise comparison as indicated: * = p < 0.05, ** = p < 0.01, *** = p < 0.001. B. 
Representative sagittal slices of averaged parametric maps of 11C-MeNER DVR of the groups with 
corresponding anatomical MRI on the left; upper row is a paramedian section through thalamus, 
red nucleus, and hypothalamus, lower row is a median section through brainstem nuclei. 11C-
MeNER images are levelled from 0.8 (dark blue) to 1.8 (red). Abbreviations: HC = healthy control, 
MRI = magnetic resonance imaging, PDRBD- = Parkinson’s disease without REM sleep behaviour 
disorder, PDRBD+ = Parkinson’s disease with REM sleep behaviour disorder. 
 
Figure 2: MRI neuromelanin contrast of the locus coeruleus and its correlation to 11C-
MeNER DVR  
A. Averaged neuromelanin MRI locus coeruleus-to-pons ratios of healthy control, PDRBD-, and 
PDRBD+ subjects (healthy control, 1.34 ± 0.05, PDRBD-, 1.30 ± 0.05, PDRBD+, 1.27 ± 0.04); error 
bars indicate standard error of the mean (SEM); group effect p < 0.001; pair-wise comparison as 
indicated: * = p < 0.05, *** = p < 0.001. B. Representative coronal sections of the dorsal brainstem 
on neuromelanin sensitive MRI of a healthy control subject with locus coeruleus-to-pons ratio of 
1.36 (upper row) and of a PDRBD+ subject with locus coeruleus-to-pons ratio of 1.25 (lower row); 
images were normalized to the intensity of the pons. The locus coeruleus is typically visible as a 
bilateral, hyper-intense, longitudinal structure in the dorsal pons in healthy subjects as seen in the 
upper row, but disappears in PDRBD+ subjects. C. Correlation of individual neuromelanin MRI 
locus coeruleus-to-pons ratios with 11C-MeNER DVRs of the thalamus (rho = 0.339, p = 0.030 for 
all groups combined). Abbreviations: DVR = distribution volume ratio, HC = healthy control, LC 
= locus coeruleus, MRI = magnetic resonance imaging, PDRBD- = Parkinson’s disease without REM 
sleep behaviour disorder, PDRBD+ = Parkinson’s disease with REM sleep behaviour disorder. 
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Figure 3: Correlation of 11C-MeNER DVR of the locus coeruleus with extent of altered REM 
sleep atonia in PD 
Each symbol represents one subject and 11C-MeNER DVR of the locus coeruleus is plotted against 
the percentage amount of REM sleep with ‘any’ activity (A), ‘tonic’ activity (B), and ‘phasic’ 
activity (C). Correlations were calculated in the PDRBD+ group only (r = -0.623, p = 0.013 for ‘any’, 
r = -0.678, p = 0.006 for ‘tonic’, and r = -0.551, p = 0.033 for ‘phasic’ activity). As control subjects 
elicited only marginal muscle activity during REM sleep, they were not included in data 
presentation. Abbreviations: DVR = distribution volume ratio, PDRBD- = Parkinson’s disease 
without REM sleep behaviour disorder, PDRBD+ = Parkinson’s disease with REM sleep behaviour 
disorder. 
Figure 4: Correlation of 11C-MeNER DVR with cognitive and autonomic assessments 
A-B. Correlation between 11C-MeNER DVR of the locus coeruleus with global cognition
expressed as averaged z-scores of all five cognitive domains (r = 0.394, p = 0.010), and between
11C-MeNER DVR of the locus coeruleus with electroencephalographic background frequency
expressed as the averaged peak frequency of O1 and O2 electroencephalography leads (r = 0.490,
p = 0.001). C-D. Correlation of changes in systolic blood pressure and diastolic blood pressure
with 11C-MeNER DVR of the hypothalamus (systolic pressure: r = 0.339, p = 0.040 and diastolic
pressure: r = 0.367, p = 0.025). Comparable correlations were obtained for 11C-MeNER DVR of
the locus coeruleus and blood pressure parameters (not shown). Abbreviations: EEG =
electroencephalography, DVR = distribution volume ratio, HC = healthy control, PDRBD- =
Parkinson’s disease without REM sleep behaviour disorder, PDRBD+ = Parkinson’s disease with
REM sleep behaviour disorder.
Table 1: Demographics and clinical characteristics  
 HC (n=12) 
PDRBD- 
(n=14) 
PDRBD+ 
(n=16) P-value 
Age 67.3 ± 6.3 65.4 ± 9.0 67.7 ± 9.3 nsǂ 
Sex (male / female) 9 / 3 10 / 4 12 / 4 ns§ 
Sniffing sticks, correct 11.1 ± 2.8 7.6 ± 2.4 6.6 ± 2.9 <0.001ǂ 1,2 
GDS-15, total 0.3 ± 0.8 0.8 ± 1.4 1.2 ± 1.4 ns¤  
MoCA, total 28.3 ± 0.9 27.2 ± 2.3 26.4 ± 2.2 ns¤ 
PD characteristics     
Disease duration [years]  5.0 ± 3.6 7.6 ± 4.6 ns¤ 
Hoehn & Yahr  2.1 ± 0.6 2.4 ± 0.5 ns¤ 
MDS-UPDRS III, total  32.6 ± 11.9 39.3 ± 10.5 nsǂ 
MDS-UPDRS III, tremor  3.1 ± 3.8 3.9 ± 3.7 ns¤ 
LEDD [mg]  547 ± 467 685 ± 342 ns¤ 
RBD characteristics     
RBDSQ, total 2.8 ± 1.7 3.3 ± 2.2 7.3 ± 3.4 0.001¤ 2,3 
Chin muscle activity:     
Tonic [% of REM sleep] 0.0 ± 0.2 0.1 ± 0.2 20.6 ± 21.7 <0.001¤ 2,3 
Phasic [% of REM sleep] 1.8 ± 1.9 4.2 ± 1.8 34.6 ± 12.5 <0.001¤ 1,2,3 
Any [% of REM sleep] 1.8 ± 1.9 4.2 ± 1.8 39.8 ± 18.2 <0.001¤ 1,2,3 
ǂ = parametric test (Student’s t-test for two groups, and one-way ANOVA for three groups, respectively), ¤ 
= non-parametric test (Mann-Whitney test for two groups, and Kruskal-Wallis test for three groups, 
respectively), § = χ² test; p-values for pair-wise comparison as indicated: 1 = HC versus PDRBD- p <0.05, 2 
= HC versus PDRBD+ p <0.05, 3 = PDRBD+ versus PDRBD- p <0.05. Abbreviations: GDS-15 = geriatric 
depression scale, HC = healthy control subject, LEDD = levodopa daily equivalent dose, MDS-UPDRS III 
= Movement Disorder Society Unified Parkinson’s disease Rating Scale part III, MoCA = Montreal 
cognitive assessment, ns = not significant, PD = Parkinson’s disease, RBD = REM sleep behavior disorder, 
RBDSQ = RBD symptom questionnaire, REM = rapid eye movement. 
 
Table 2: Cognitive and autonomic assessment of healthy controls and PD patients  
 HC (n=12) 
PDRBD- 
(n=14) 
PDRBD+ 
(n=16) P-value 
Cognitive testing     
Memory (z-score) -0·09 ± 0·92 -0·28 ± 1·01 -0·65 ± 0·85 nsǂ 
Working memory (z-score) -0·04 ± 0·65 -0·01 ± 0·78 -0·44 ± 0·64 nsǂ  
Executive function (z-score) 0·09 ± 0·91 0·07 ± 1·01 -0·23 ± 1·05 ns¤ 
Language (z-score) 0·35 ± 0·69 0·14 ± 0·60 -0·27 ± 1·11 ns¤ 
Visuospatial function (z-score) 0·00 ± 0·62 -0·26 ± 0·72 -0·73 ± 0·82 0·037ǂ 2 
Global performance (z-score) 0·08 ± 0·61 -0·07 ± 0·67 -0·46 ± 0·62 nsǂ 
Mild cognitive impairment [%] 16·7 21·4 50 ns§ 
EEG     
Background frequency [Hz] 9·79 ± 0·82 9·29 ± 0·83 8·52 ± 1·16 0·007ǂ 2,3 
Alpha power [µV²] 22·55 ± 23·55 30·85 ± 26·94 28·54 ± 26·61 ns¤ 
Theta power [µV²] 3·88 ± 2·72 9·95 ± 10·16 20·85 ± 20·41 0·009¤ 2 
Alpha/theta ratio 5·03 ± 2·32 4·67 ± 2·62 2·39 ± 1·90 0·008ǂ 2,3 
Autonomic assessment     
Antihypertensive medication [%] 16·7 28·6 21·4 ns§ 
SCOPA-AUT, total 5·0 ± 2·4 12·6 ± 5·6 12·1 ± 7·8 <0·001¤ 1,2 
BP changes upon tilting:     
Orthostatic hypotension [%] 0 28·6 50 0·026§ 
Systolic pressure [mmHg] 7·5 ± 12·9 -4·2 ± 16·7 -12·2 ± 17·9 0·019ǂ 2 
Diastolic pressure [mmHg] 7·2 ± 6·7 4·5 ± 10·2 2·8 ± 9·1 nsǂ 
ǂ = one-way ANOVA with post-hoc testing, ¤ = Kruskal-Wallis and Mann-Whitney test for pair-wise 
comparison, § = χ² test; p-values for pair-wise comparison as indicated: 1 = HC versus PDRBD- p <0·05, 2 = 
HC versus PDRBD+ p <0·05, 3 = PDRBD+ versus PDRBD- p <0·05. Abbreviations: BP = blood pressure, EEG 
= electroencephalography, MCI = mild cognitive impairment, ns = not significant, PD = Parkinson’s 
disease, RBD = REM sleep behavior disorder, SCOPA-AUT = scales for outcomes in PD - autonomic. 
 




